首页> Journal of gastrointestinal oncology> Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice.

Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice.

导出 OA

翻译打印收藏纠错

第一作者： Huaqiang,Bi

第一单位： Department of Hepatobiliary Surgery, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.

作者： Huaqiang,Bi ^[1] ; Jun,Pei ^[1] ; Kuansheng,Ma ^[1] ; Yanling,Zhang ^[2] ; Giuseppe,Aprile ^[3] ; Dimitrios,Moris ^[4] ; Nahum,Méndez-Sánchez ^[5] ; Hrishikesh,Samant ^[6] ; Ximin,Sun ^[1] ; Feng,Xia ^[1]

作者单位： Department of Hepatobiliary Surgery, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China. ^[1] Department of Oncology, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China. ^[2] Department of Medical Oncology, San Bortolo General Hospital, Vicenza, Italy. ^[3] Department of Surgery, Duke University Medical Center, Durham, NC, USA. ^[4] Liver Research Unit, Medica Sur Clinic and Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico. ^[5] Division of Gastroenterology and Hepatology, LSU Health Science Center, Shreveport, LA, USA. ^[6]

关键词 Hepatocellular carcinoma (HCC)anti-program death-1 inhibitors immunotherapy objective response rate (ORR)progression-free survival (PFS)

DOI 10.21037/jgo-23-618

PMID 38482245

发布时间 2024-03-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交